2018 Omenn Lecture presented by Atul Butte, PhD

"Translating a Trillion Points of Data into Therapies, Diagnostics, and New Insights into Disease"

Presented by Atul Butte PhD (UCSF School of Medicine)

Sponsored by The University of Michigan Department of Computational Medicine and Bioinformatics

Abstract

There is an urgent need to take what we have learned in our new “genome era” and use it to create a new system of precision medicine, delivering the best preventative or therapeutic intervention at the right time, for the right patients. Dr. Butte's lab at the University of California, San Francisco builds and applies tools that convert trillions of points of molecular, clinical, and epidemiological data -- measured by researchers and clinicians over the past decade and now commonly termed “big data” -- into diagnostics, therapeutics, and new insights into disease. Several of these methods or findings have been spun out into new biotechnology companies. Dr. Butte, a computer scientist and pediatrician, will highlight his lab’s recent work, including the use of publicly-available molecular measurements to find new uses for drugs including new therapies for autoimmune diseases and cancer, discovering new druggable targets in disease, the evaluation of patients and populations presenting with whole genomes sequenced, integrating and reusing the clinical and genomic data that result from clinical trials, discovering new diagnostics include blood tests for complications during pregnancy, and how the next generation of biotech companies might even start in your garage.

Gilbert S. Omenn Annual Lectureship

The Annual Gilbert S. Omenn Lecture series features high-profile scientists discussing a variety of scientific topics and issues around bioinformatics, data science and the development of this field.

This annual event gathers the Department of Computational Medicine and Bioinformatics and the Center of Computational Medicine and Bioinformatics scientific communities while inviting a larger audience within U-M and beyond.